Sunday, October 25, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 5, 2026

Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider

View original at globenewswire.com
Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider Austin, United States, Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Human Vaccines Market is driven by the rising awareness of preventive healthcare, expansion of national immunization programs, and rising cases of infectious and chronic diseases

    80% confidence
  • Online Pharmacy is expected to grow at the fastest CAGR of 6.78% during 2026–2033

    80% confidence
  • mRNA vaccines are expected to grow at the fastest CAGR of 7.12% during 2026–2033

    80% confidence
  • Research & Academic Institutes are forecasted to register the fastest CAGR of 7.21% during 2026–2033

    80% confidence
  • Intradermal delivery is projected to expand at the fastest CAGR of 6.45% during the forecast period

    80% confidence
  • The Human Vaccines Market size was valued at USD 44.26 billion in 2025 and is expected to reach USD 62.45 billion by 2033, growing at a CAGR of 4.43% during the forecast period of 2026-2033

    80% confidence
  • Hospital Pharmacy held the largest share of 45.87% in 2025

    80% confidence
  • Adult vaccines held the largest share of 39.61% in 2025

    80% confidence
  • Geriatric vaccines are expected to grow at the fastest CAGR of 6.98% during 2026–2033

    80% confidence
  • HPV vaccines are anticipated to record the fastest CAGR of 7.34% through 2026–2033

    80% confidence
  • Government vaccination programs are an essential factor in the development of the market

    80% confidence
  • Intramuscular vaccines accounted for the highest market share of 46.32% in 2025

    80% confidence
  • The market is challenged by high development costs, complex manufacturing processes, and strict regulatory requirements

    80% confidence
  • The Asia Pacific Human Vaccines Market is the fastest-growing globally, projected to register a CAGR of 5.89% during 2026–2033

    80% confidence
  • Inactivated vaccines held the largest market share of 28.74% in 2025

    80% confidence
  • COVID-19 vaccines dominated with a 31.25% share in 2025

    80% confidence
  • North America dominated the Human Vaccines Market, accounting for a 34.56% market share in 2025

    80% confidence
  • The U.S. Human Vaccines Market is expected to grow from USD 11.72 billion in 2025 to USD 15.17 billion by 2033, registering a CAGR of 3.30% during the forecast period

    80% confidence
  • Hospitals accounted for the largest share of 53.12% in 2025

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise Software Races to Govern and Consolidate Around Agentic AI
Enterprise software vendors are repositioning around autonomous AI agents. Salesforce is acquiring Braze, ServiceNow is launching agent governance tools (AI Passport, Super Intelligence Control Tower), SAP is pushing its 'Autonomous Enterprise', and Zeta is launching AthenaOS and its own inference model. Palantir is embedding itself in banking, aviation and sovereign AI infrastructure through partnerships with Customers Bank, Surf Air, Ondas and Armada. Governance, data sovereignty and enforced policy are emerging as preconditions for regulated sectors like finance. Investors such as Norwest see room to disrupt ERP and finance software, and they caution that AI should not be trusted with financial calculations. Consolidation and shareholder disputes (Salesforce/Braze, Tiny/Oso Cloud, ZenaTech/Boardwalktech) show the market reshaping.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider — Source | Via News | Via News